Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,601.00-0.41%ETH$2,698.06-0.77%GOLD$4,194.40+0.17%OIL$89.74+0.34%
Smart Investors Daily
SID Premium
AN

NASDAQ · ANL

Adlai Nortye Ltd.

Healthcare · Biotechnology

$15.04

Down-$0.58 (-3.86%)

Updated Oct 6, 2026, 10:16 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
245.52M
P/E ratio
-1.61
Dividend yield
0.00%
52-week range
$0.88 – $17.25
Volume
460.58K
Avg. volume
920.81K

Price performance · ANL

ANL price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

ANL closed at $15.04 after 20 trading sessions, down 3.03% for the selected period.

Last close
$15.04
Period change
-3.03%
Period low
$14.70
Period high
$16.60
Daily close
View OHLC price history
ANL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$14.80$15.82$14.34$15.04460.58K
Oct 2, 2026$15.76$15.80$14.825$15.0977K
Oct 1, 2026$16.00$16.20$15.5358$15.76124.79K
Sep 30, 2026$15.87$16.31$15.50$16.0093.95K
Sep 29, 2026$15.26$15.82$15.11$15.6563.03K
Sep 28, 2026$15.70$15.855$15.095$15.4063.51K
Sep 25, 2026$16.16$16.16$15.375$15.5334.8K
Sep 24, 2026$15.51$16.05$14.70$15.83144.26K
Sep 23, 2026$16.47$16.9499$15.60$15.75218.13K
Sep 22, 2026$15.80$16.73$15.655$16.60107.18K
Sep 21, 2026$15.99$16.16$15.045$15.5792.59K
Sep 18, 2026$15.13$15.92$15.13$15.74156.62K
Sep 17, 2026$15.89$16.25$15.00$15.2891.5K
Sep 16, 2026$15.16$15.75$14.925$15.52220.83K
Sep 15, 2026$15.92$16.19$14.87$15.00171.3K
Sep 14, 2026$15.18$16.10$15.13$15.93175.55K
Sep 11, 2026$15.32$16.00$15.20$15.21228.74K
Sep 10, 2026$14.97$15.78$14.70$15.09318.22K
Sep 9, 2026$15.44$15.94$14.42$14.695161.83K
Sep 8, 2026$15.12$16.12$14.82$15.51404.96K

Latest ANL news

The latest Smart Investors Daily articles mentioning ANL.

Stock researchCompany · Overview

ANL research

Overview

Company profile and research snapshot.

Company profile

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ANL recent ratings
DateFirmRatingTarget
Sep 10, 2026JefferiesBuy—
Sep 8, 2026HC Wainwright & Co.Buy—
Jun 22, 2026Cantor FitzgeraldOverweight—
May 28, 2026OppenheimerOutperform—
May 14, 2026Jones TradingBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience, with a focus on biotechnology and oncology. “We are pleased to welcome Chris to Adl

Yahoo · Sep 15, 2026

4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress

Why the AN4035 trial move matters for Adlai Nortye Group stock Adlai Nortye Group (NasdaqGM:ANL) has just dosed the first patient in its global Phase I trial for AN4035 and secured a Study May Proceed letter from the FDA, clearing expansion into the United States. The fresh AN4035 milestone comes after a strong run in Adlai Nortye Group’s stock, with a very large year-to-date share price return and a 1-year total shareholder return of about 8x. Recent 30-day and 90-day share price returns of...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By